You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,763,945


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,763,945
Title:Methods and formulations for modulating Lyn kinase activity and treating related disorders
Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
Inventor(s): Reaume; Andrew G. (Exton, PA), Saporito; Michael S. (Exton, PA)
Assignee: Melior Pharmaceuticals I, Inc. (Exton, PA)
Application Number:14/941,473
Patent Claims:1. A method of treating dyslipidemia or altering lipid metabolism in a mammal comprising administering to the mammal in need thereof an effective amount of a composition comprising a compound of formula: ##STR00010## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is methyl and n is 1; X is a halogen; and m is 0 or 1.

2. The method of claim 1, wherein the compound is a compound of formula: ##STR00011## or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein the lipid metabolism includes at least one aspect chosen from total blood lipid content, blood HDL cholesterol, blood LDL cholesterol, blood VLDL cholesterol, blood triglyceride, blood Lp(a), blood apo A-I, blood apo E, and blood non-esterified fatty acids.

4. The method of claim 1, wherein the compound is administered orally in an amount of 0.5 mg to 20 mg per kilogram of body weight or 1 mg to 10 mg per kilogram of body weight.

5. The method of claim 1, wherein the compound is administered intravenously in an amount of 0.1 mg to 35 mg per kilogram of body weight or 1 mg to 10 mg per kilogram of body weight.

6. The method of claim 1, wherein the compound is administered intranasally in an amount of 0.01 pg to 1 mg per kilogram of body weight.

7. The method of claim 1, wherein the compound is administered concurrently with the administration of another therapeutic agent chosen from a statin, a PPAR agonist, a bile-acid-binding resin, niacin, nicotinic acid, a RXR agonist, an anti-obesity drug, a hormone, an insulin secretagogue, a tyrophostine, a sulfonylurea-based drug, metformin, an .alpha.-glucosidase inhibitor, an apo A-I agonist, apolipoprotein E, a cardiovascular drug, and a chemotherapeutic agent.

8. The method of claim 7, wherein: the statin is chosen from atorvastatin, pravastatin, fluvastatin, lovastatin, simvastatin, and cerivastatin; the PPAR agonist is chosen from troglitazone, pioglitazone, rosiglitazone, ciglitazone, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidined- ione, AD 5075, WAY-120,744, englitazone, darglitazone, gemfibrozil, fenofibrate, clofibrate, and ciprofibrate; the bile-acid-binding resin is chosen from cholestyramine and colestipol hydrochloride; the RXR agonist is chosen from LG 100268, LGD 1069, 9-cis retinoic acid, 2-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-cyclopropyl)-p- yridine-5-carboxylic acid, and 4-((3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)2-carbonyl)-benzo- ic acid; the anti-obesity drug is chosen from .beta.-3 receptor agonists, sibutramine, bupropion, fluoxetine, and phentermine; the hormone is chosen from thyroid hormone, and estrogen and insulin; the insulin secretagogue is chosen from forskolin, dibutryl cAMP, and isobutylmethylxanthine; the tyrophostine is tyrophostine 51; the sulfonylurea-based drug is chosen from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, and tolcyclamide; the .alpha.-glucosidase inhibitor is chosen from acarbose and miglitol; the apo A-I agonist is the Milano form of apo A-I (apo A-IM); the cardiovascular drug is chosen from methyldopa, diazoxide, hydralazine, phentolamine, amrinone, milrinone, enoximone, fenoximone, imazodan, sulmazole, ranitine, bosentan, and rezulin and the chemotherapeutic agent is chosen from methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposides, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, and docetaxel.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.